CWCaroline Wilson

Caroline Wilson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline Wilson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sperm Cell Painting: A Mechanism Driven Approach for Drug Discovery in Human Spermatozoa

    by Zoe C. Johnston, Franz S. Gruber, Rachel Myles, Shruti V. Kane, Anthony Richardson, David P. Day, Caroline Wilson, Kevin D. Read, Ian H. Gilbert, Sarah Martins da Silva, et al.

    We have adapted the cell painting assay developed by Carpenter and colleagues on cultured U2OS cells to human spermatozoa. In Sperm Cell Painting (SCP) we assemble an image-based quantitative fingerprint of the functional state of sperm. We use this assay to gain insight into the mechanism of action of compounds that modify sperm function and as a platform for contraceptive discovery.

  • Open Access

    Sperm Toolbox – A selection of small molecules to study human spermatozoa

    by Franz S. Gruber, Anthony Richardson, Zoe C. Johnston, Rachel Myles, Neil Norcross, David Day, Irene Georgiou, Laura Sesma Sanz, Caroline Wilson, Kevin D. Read, et al.

    Male contraceptive options and infertility treatments are limited. To help overcome these limitations we established a small molecule library as a toolbox for assay development and screening campaigns using human spermatozoa. We have profiled all compounds in our automated high-throughput screening platform and provide the dataset, which allows direct side-by-side comparisons of compound effects and assays using live human spermatozoa.


  • Open Access

    Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform

    by Franz S Gruber, Zoe C Johnston, Neil R Norcross, Irene Georgiou, Caroline Wilson, Kevin D Read, Ian H Gilbert, Jason R Swedlow, Sarah Martins da Silva, Christopher L R Barratt

    Can a high-throughput screening (HTS) platform facilitate male fertility drug discovery? An HTS platform identified a large number of compounds that enhanced sperm motility. Several efforts to find small molecules modulating sperm function have been performed but none have used high-throughput technology. Healthy donor semen samples were used and samples were pooled (3–5 donors per pool). Primary screening was performed singly; dose–response screening was performed in duplicate (using independent donor pools). Spermatozoa isolated from healthy donors were prepared by density gradient centrifugation and incubated in 384-well plates with compounds (6.25 μM) to identify those compounds with enhancing effects on motility. Approximately 17 000 compounds from the libraries, ReFRAME, Prestwick, Tocris, LOPAC, CLOUD and MMV Pathogen Box, were screened. Dose–response experiments of screening hits were performed to confirm the enhancing effect on sperm motility. Experiments were performed in a university setting. From our primary single concentration screening, 105 compounds elicited an enhancing effect on sperm motility compared to dimethylsulphoxide-treated wells. Confirmed enhancing compounds were grouped based on their annotated targets/target classes. A major target class, phosphodiesterase inhibitors, were identified, in particular PDE10A inhibitors as well as number of compounds not previously known to enhance human sperm motility, such as those related to GABA signalling. N/A. Although this approach provides data about the activity of the compound, it is only a starting point. For example, further substantive experiments are necessary to provide a more comprehensive picture of each compound’s activity, the effect on the kinetics of the cell populations and subpopulations, and their potential mechanisms of action. Compounds have been tested with prepared donor spermatozoa, incubated under non-capacitating conditions, and only incubated with compounds for a relatively short period of time. Therefore, the effect of compounds under different conditions, for example in whole semen, for longer incubation times, or using samples from patient groups, may be different and require further study. All experiments were performed in vitro. This phenotypic screening assay identified a large number of compounds that increased sperm motility. In addition to furthering our understanding of human sperm function, for example identifying new avenues for discovery, we highlight potential compounds as promising start-point for a medicinal chemistry programme for potential enhancement of male fertility. Moreover, with disclosure of the results of screening, we present a substantial resource to inform further work in the field. This study was supported by the Bill and Melinda Gates Foundation, Scottish Funding Council and Scottish Universities Life Science Alliance. C.L.R.B. is Editor for RBMO. C.L.R.B. receives funding from Chief Scientists Office (Scotland), ESHRE and Genus PLC, consulting fees from Exscientia and lecture fees from Cooper Surgical and Ferring. S.M.d.S. is an Associate Editor of Human Reproduction, and an Associate Editor of Reproduction and Fertility. S.M.d.S. receives funding from Cooper Surgical and British Dietetic Society. No other authors declared a COI.


  • Open Access

    Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform

    by Franz S. Gruber, Zoe C. Johnston, Neil R. Norcross, Irene Georgiou, Caroline Wilson, Kevin D. Read, Ian H. Gilbert, Jason R. Swedlow, Sarah Martins de Silva, Christopher Lr Barratt

    Study question Can a high-throughput screening platform facilitate male fertility drug discovery? Summary answer A high-throughput screening platform identified a large number of compounds that enhanced sperm motility. What is known already Several efforts to find small molecules modulating sperm function have been performed but not using high-throughput technology. Study design, size, duration Healthy donor semen samples were used and samples were pooled (3-5 donors per pool). Primary screening was performed in singlicate; dose-response screening was performed in duplicate (independent donor pools). Participants/materials, setting, methods Spermatozoa isolated from healthy donors were prepared by density gradient centrifugation and incubated in 384-well plates with compounds (6.25 uM) to identify those compounds with enhancing effects on motility. A total of ∼17,000 compounds from the following libraries: ReFRAME, Prestwick, Tocris, LOPAC, CLOUD and MMV Pathogen Box were screened. Dose response experiments of screening hits were performed to confirm the enhancing effect on sperm motility. Experiments were performed in a University setting. Main results and the role of chance From our primary single concentration screening, 105 compounds elicited an enhancing effect on sperm motility compared to DMSO treated wells. Confirmed enhancing compounds were grouped based on their annotated targets/target classes. A major target class, phosphodiesterase inhibitors, were identified in particular PDE10A inhibitors as well as number of compounds not previously identified/known to enhance human sperm motility such as those related to GABA signaling. Limitations, reasons for caution Compounds have been tested with prepared donor spermatozoa and only incubated for a short period of time. Therefore, the effect of compounds on whole semen or with longer incubation time may be different. All experiments were performed in vitro. Wider implications of the findings This phenotypic screening assay identified a large number of compounds that increased sperm motility. In addition to furthering our understanding of human sperm function, for example identifying new avenues for discovery, we highlight potential inhibitors as promising start-point for a medicinal chemistry programme for potential enhancement of male infertility. Moreover, with disclosure of the results of screening we present a substantial resource to inform further work in the field Study funding/competing interest(s) This study was supported by the Bill and Melinda Gates Foundation and Scottish Funding Council and Scottish Universities Life Science Alliance.


  • The University: Industry Interface in the Generation of Intellectual Property

    by John F. Pickering, Duncan N. Matthews, Caroline Wilson, John Kirkland